Strategy
Charles River Sets First 2030 Targets After Long Downturn, Backed by $300 Million Cost Program; Shares Jump 6%
The drug-development services group told its investor day it expects 5% to 7% organic revenue growth a year through 2030 and a roughly 24% operating margin.
AF
By Anna Ferreira
Sep 25, 2026 · 3 min read
Charles River Laboratories laid out its first credible long-range targets since a multi-year downturn at an investor day on Sept. 24, and investors responded: the stock closed at $294.44, up $17.11 or 6.17%, among the day's strongest performers in the S&P 500.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.